Ainos, Nisshinbo Micro Devices & Inabata begin phase 2 of VOC co-development powered by AI nose, accelerating the digitalization of smell

Ainos, Inc., a diversified healthcare company, announced that it is initiating the second phase of co-development of a volatile organic compound (VOC) sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices Inc. (NISD) and Taiwan Inabata Sangyo Co. (Inabata). The parties aim to finalize the prototype in the third quarter of 2024 and subsequently prepare for mass production.

"I'm thrilled to say that Ainos, NISD and Inabata are initiating the second phase just four months after our initial co-development announcement in August 2023. This rapid progress underscores our unwavering commitment to digitizing smell by pioneering VOC sensing's potential across diverse industries. The collaboration signals an era of innovation for our AI Nose technology, expanding the potential application of our AI-powered VOC sensing technology to telehealth, automotive, industrial, and environmental safety, thereby broadening our addressable market. We look forward to successfully launching the product in the second half of 2024," said Chun-Hsien (Eddy) Tsai, chairman, president and CEO of Ainos.

In the second phase, the parties plan to finalize the platform's functionality, specifications, and market positioning for the platform. In addition, the parties will also focus on developing the solution's key hardware and software aspects, including manufacturing, form factor, user interface, and safety requirements.

Under the co-development, Ainos and NISD will co-develop a VOC sensing platform that leverages Ainos' digital nose intellectual properties, the AI Nose platform. The co-developed platform is intended to be used in a variety of applications including telehealth, automotive, industrial, and environmental safety. Inabata will provide business logistics for the program and liaise between Ainos and NISD.

The Parties have a shared vision for the future of VOC sensing technology across a variety of applications, including telehealth, automotive, industrial, and environmental safety. To achieve this vision, the Parties have committed to collaborating on the development of innovative technologies by leveraging Ainos' cutting-edge artificial intelligence (AI) algorithm and digital nose technologies. These technologies have been developed over the past decade, and are protected by over 50 active and pending patents. By combining their expertise and resources, the Parties aim to create a new standard in VOC sensing and analysis, utilizing Ainos' deep-learning algorithm and cloud-based big data analysis to provide unparalleled accuracy and insight.

Headquartered in San Diego, California, Ainos, Inc. is a diversified healthcare company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications.

Nisshinbo Micro Devices Inc. provides analog solutions through electronic devices and microwave products. The company's comprehensive analog solutions serve a broad range of industries including automotives, industrials and consumers.

Founded in 1989, Taiwan Inabata Sangyo Co., Ltd is a fully owned Taiwanese subsidiary of Inabata & Co. Ltd. The parent company Inabata & Co. Ltd. is a multifaceted trading company operating in four business segments: Information & electronics, plastics, chemicals and life industry.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!